#United States #New York #Securities Class Action #revenue decline #Embecta Corp

Investors Alert: Embecta Corp. Faces Class Action Deadline

Investors in Embecta Corp. (NASDAQ: EMBC) should be aware of a crucial deadline related to an ongoing securities class action lawsuit. This alert comes from Levi & Korsinsky, LLP, a well-known law firm specializing in securities litigation. The lawsuit is set to take place for those who purchased Embecta securities between November 25, 2025, and May 4, 2026, with the deadline for filing claims being August 17, 2026.

The Case: An Overview

The lawsuit seeks to recover losses for investors following a sharp decline in Embecta’s stock prices. The company revealed that its U.S. business saw a revenue drop of more than 14%, causing a dramatic fall in the stock value. Shares plummeted by $5.35 or over 57% after the company confessed to internal struggles that had previously been masked by optimistic revenue projections. Investors are encouraged to evaluate their eligibility for compensation given these developments.

Financial Struggles Uncovered

The crux of the lawsuit includes claims that Embecta misled its investors about the stability and growth of its pen needle segment, crucial to its earnings. During a time when the company reassured investors about its revenue forecasts, the reality struck with a reported revenue decline of 14.4% for the second quarter of 2026. This stark contrast to prior expectations raises questions about the validity of statements made by Embecta’s management.

The lawsuit specifically highlights an alarming revenue shortfall within the pen needle category, which has been a major profit driver for Embecta, accounting for approximately 70% of the revenue guidance drop. Multiple factors contributed to this downturn, including:

• - Significant market loss attributed to a singular major customer which caused an estimated $25 million revenue deficit.
• - A noted softness in the retail market, further amplifying the revenue shortfall by about $20 million.
• - Inventory reductions and pricing pressures pushing an additional $8 million loss.
• - Increased competition causing patients to opt for alternate, lower-priced options, contributing to an overall decline in retail volume.

The Declining Revenue Picture

The extent of the revenue impact was more severe than initially reported due to a shift in consumer behavior, complicating the scenario for Embecta. Customers migrating to competitor products mostly came from plans that favored different products, leading to greater losses than the surface-level declines suggested. Additionally, smaller regional pharmacies, which typically had higher net revenue per unit for Embecta, faced challenges contributing to the revenue decline further.

The situation only worsened as Embecta reduced its forecasts for free cash flow significantly from $180–200 million down to between $95-105 million. This revision, paired with an increase in tax rates, lowered expected earnings per share further, decreasing by about $0.10 due to reduced profitability.

Actions for Investors

For those who bought shares during the impacted timeframe and witnessed financial losses, now is the time to consider your options. Levi & Korsinsky encourages you to assess your position and seek potential compensation without upfront costs. Investors are advised to gather relevant brokerage records, including share quantities, purchase dates, and prices paid, as this data will be essential for the evaluation process.

Deadline Implications

While the deadline for obtaining lead plaintiff status is August 17, 2026, being a part of the class action allows investors to pursue any potential recovery from losses even if they no longer hold shares. It is crucial to understand that eligibility depends on the timing of purchases and documented losses, not current share ownership.

Joseph E. Levi, Esq., a representative from Levi & Korsinsky, remarked, “The complaint raises serious questions about whether investors received accurate information about the trajectory of Embecta’s U.S. pen needle business and the sustainability of the Company's fiscal year 2026 guidance.” Investors intrigued by this call to action should directly reach out to the firm for further assistance.

Conclusion

As this case unfolds, it serves as a reminder of the importance of transparency in corporate disclosures and the potential consequences of misleading information. Investors must stay informed and proactive in the face of such developments to protect their financial interests.

Contact Details:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Email: [email protected]
Phone: (212) 363-7500